These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19273160)

  • 1. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.
    Ruter J; Barnett BG; Kryczek I; Brumlik MJ; Daniel BJ; Coukos G; Zou W; Curiel TJ
    Front Biosci (Landmark Ed); 2009 Jan; 14(5):1761-70. PubMed ID: 19273160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting regulatory T cells.
    Ménétrier-Caux C; Curiel T; Faget J; Manuel M; Caux C; Zou W
    Target Oncol; 2012 Mar; 7(1):15-28. PubMed ID: 22327882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
    Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
    Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    Dannull J; Su Z; Rizzieri D; Yang BK; Coleman D; Yancey D; Zhang A; Dahm P; Chao N; Gilboa E; Vieweg J
    J Clin Invest; 2005 Dec; 115(12):3623-33. PubMed ID: 16308572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tregs and rethinking cancer immunotherapy.
    Curiel TJ
    J Clin Invest; 2007 May; 117(5):1167-74. PubMed ID: 17476346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
    Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
    Morse MA; Hobeika AC; Osada T; Serra D; Niedzwiecki D; Lyerly HK; Clay TM
    Blood; 2008 Aug; 112(3):610-8. PubMed ID: 18519811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.
    Tan C; Reddy V; Dannull J; Ding E; Nair SK; Tyler DS; Pruitt SK; Lee WT
    J Transl Med; 2013 Jun; 11():148. PubMed ID: 23768240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T cells in cancer immunotherapy.
    Nishikawa H; Sakaguchi S
    Curr Opin Immunol; 2014 Apr; 27():1-7. PubMed ID: 24413387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
    Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
    Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.
    Hurez V; Daniel BJ; Sun L; Liu AJ; Ludwig SM; Kious MJ; Thibodeaux SR; Pandeswara S; Murthy K; Livi CB; Wall S; Brumlik MJ; Shin T; Zhang B; Curiel TJ
    Cancer Res; 2012 Apr; 72(8):2089-99. PubMed ID: 22496463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy.
    Dees S; Ganesan R; Singh S; Grewal IS
    Eur J Immunol; 2021 Feb; 51(2):280-291. PubMed ID: 33302322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cells in cancer immunotherapy.
    Tanaka A; Sakaguchi S
    Cell Res; 2017 Jan; 27(1):109-118. PubMed ID: 27995907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD25+ CD4+ regulatory T-cells in cancer.
    Linehan DC; Goedegebuure PS
    Immunol Res; 2005; 32(1-3):155-68. PubMed ID: 16106066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cells in ovarian cancer: biology and therapeutic potential.
    Barnett B; Kryczek I; Cheng P; Zou W; Curiel TJ
    Am J Reprod Immunol; 2005 Dec; 54(6):369-77. PubMed ID: 16305662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target.
    Mousavi-Niri N; Naseroleslami M; Hadjati J
    Hum Vaccin Immunother; 2019; 15(3):620-624. PubMed ID: 30633616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
    Johnson BD; Jing W; Orentas RJ
    J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.